Reply to 'Epidemiological analysis of second primary malignancies in more than 9500 patients treated with imatinib' by Pilot et al.
Roy
L
L
1Department of Oncology-Hematology and Cell Therapy, Clinical Research Centre, Poitiers, France.
Guilhot
J
J
Martineau
G
G
Guilhot
F
F